Menu

PROGRAM
Friday, September 8th

7:30-8:50 am

Registration/Check-in

8:50-9:00 am

Welcoming Remarks
Gerry Boss, MD, University of California San Diego


SESSION I
Diana Hargreaves, PhD - Salk Institute (Moderator)

9:00-9:30 am

CD19 CAR-T Cells: Prototypes for the Living Drug Concept
Michel Sadelain, MD, PhD - Memorial Sloan Kettering Cancer Center

9:30-9:40 am

Discussion

9:40-10:10 am

Remote and Noninvasive Control of Genetics by Ultrasound for Cell Therapy Against Solid Tumors
Peter Yingxiao Wang, PhD, University of Southern California

10:10-10:20 am

Discussion

10:20-10:40 am

Break


SESSION II
Cosimo Commisso, PhD - Sanford Burnham Prebys (Moderator)

10:40-11:10 am

Off-The-Shelf NK Cell Strategies to Treat Cancer
Jeffrey S. Miller, MD - University of Minnesota

11:10-11:20 am

Discussion

11:20-11:50 am

Engineering Human Pluripotent Stem Cells to Produce Immune Cells with Improved Anti-tumor Activity
Dan Kaufman, MD, PhD - University of California San Diego

11:50-12:00 pm

Discussion

12:00-1:30 pm

Lunch

1:30-2:00 pm

Bench to Bedside Translation of a Novel Switchable CAR-T Cell Platform
Travis Young, PhD - Calibr at Scripps Research

2:00-2:10 pm

Discussion


SESSION III
Jing Yang, PhD - University of California San Diego (Moderator)

2:10-2:40 pm

From Cancer to Aging: Harnessing CAR-T Cells to Deconstruct Senescence
Corina Amor Vegas, MD, PhD - Cold Spring Harbor Laboratory

2:40-2:50 pm

Discussion

2:50-3:10 pm

Break

3:10-3:40 pm

Augmenting CAR-T with Engineered Interleukin-18
Aaron Ring, MD, PhD - Fred Hutchinson Cancer Center

3:40-3:50 pm

Discussion

3:50-4:20 pm

Bridging Synthetic Immunology and Genome Editing to Advance T Cell Therapies
Justin Eyquem, PhD - University of California San Francisco

4:20-4:30 pm

Discussion

4:30 pm

Closing Remarks
Dan Kaufman, MD, PhD - University of California San Diego